Advertisement

Advertisement
Hematologic Malignancies

FDA Approves Rituximab Plus Chemotherapy for Several Pediatric Hematologic Malignancies

On December 2, the U.S. Food and Drug Administration (FDA) approved rituximab (Rituxan) in combination with chemotherapy for pediatric patients (≥ 6 months to < 18 years old) with previously untreated, advanced-stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia.

 

 

 

 

 

 

 

 

Skin Cancer
Genomics/Genetics
Immunotherapy

DREAMseq Trial: In Advanced Melanoma With BRAF Mutations, Start With Immunotherapy

In the treatment of patients with advanced melanoma containing BRAF mutations, initial treatment with an immunotherapy combination...

 

 

 

 

 

 

 

Breast Cancer

Long-Term Follow-up of monarchE: Benefit of Abemaciclib Plus Endocrine Therapy Maintained in Early High-Risk Breast Cancer

Longer-term follow-up of the global phase III monarchE trial showed an increasing benefit for adding abemaciclib to endocrine therapy...

 

 


Advertisement
COVID-19

Effect of the COVID-19 Pandemic on Cancer Imaging

Significant decreases in CT imaging for cancer persisted even after the peak of the COVID-19 pandemic in 2020...

COVID-19

ASCO Coronavirus Resources

As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...

Advertisement




Kidney Cancer

Robert J. Motzer, MD, on RCC: Quality of Life for Patients Treated With Lenvatinib-Based Therapy vs Sunitinib

Gynecologic Cancers
Pancreatic Cancer

Electronic Olfaction System Under Study as Screening Tool for Pancreatic and Ovarian Cancers

An odor-based test that detects vapors emanating from blood samples was able to distinguish between benign and pancreatic and ovarian cancer cells with up to 95% accuracy, according to a new study presented by Johnson et al during the 2021 ASCO Annual Meeting (Abstract 5544). The findings suggest...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Lung Cancer
Genomics/Genetics
Immunotherapy

Pasi A. Janne, MD, PhD, on NSCLC: Patritumab Deruxtecan to Target HER3

COVID-19
Global Cancer Care

Effect of the COVID-19 Pandemic on Delivery of Oncology Services in India

In a study reported in The Lancet Oncology, Ranganathan et al quantified the enormous impact of the COVID-19 pandemic on delivery of cancer services in India. Study Details The study involved data from 41 cancer centers across the nation. The delivery of oncology services between March 1 and May...

Leukemia
Genomics/Genetics

Addition of Gemtuzumab Ozogamicin to Conventional Background Chemotherapy in Pediatric Patients With KMT2A-Rearranged AML

As reported in the Journal of Clinical Oncology by Pollard et al, a subgroup of pediatric patients with KMT2A-rearranged acute myeloid leukemia (AML) in the phase III Children’s Oncology Group AAML0531 trial had improved outcomes with the addition of the CD33-targeting agent gemtuzumab ozogamicin...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Lung Cancer
Immunotherapy

Byoung Chul Cho, MD, PhD, on NSCLC: Amivantamab Plus Lazertinib for Treatment of Relapsed Disease

Kidney Cancer
Immunotherapy

Real-World Survival Outcomes With Various Treatment Regimens for Metastatic Renal Cell Carcinoma

In a real-world retrospective propensity-matched cohort study reported in JAMA Network Open, Chakiryan et al found that both first-line immunotherapy and combined treatment with targeted therapy plus immunotherapy were associated with improved overall survival vs targeted therapy alone in patients...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...